TScan Therapeutics Inc. (TCRX)
NASDAQ · Healthcare
TScan Therapeutics Inc. Shareholder Equity 2020–2025
TScan Therapeutics Inc. annual shareholder equity history from 2020 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- TScan Therapeutics Inc. shareholder equity as of December 31, 2025: 123.1M, a 48.91% decrease year-over-year.
- TScan Therapeutics Inc. shareholder equity for 2025 were 123.1M, a 48.91% decrease from 2024.
- TScan Therapeutics Inc. shareholder equity for 2024 were 241.0M, a 59.72% increase from 2023.
- TScan Therapeutics Inc. shareholder equity for 2023 were 150.9M, a 51.73% increase from 2022.
- TScan Therapeutics Inc. shareholder equity for 2022 were 99.4M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| TScan Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $123 |
| 2024 | $241 |
| 2023 | $151 |
| 2022 | $99 |
| 2021 | $161 |
| 2020 | $-42 |
TScan Therapeutics Inc. Shareholder Equity — FAQ
TScan Therapeutics Inc. (TCRX) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see TCRX's shareholder equity history?
The chart and table above show TScan Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.